ME Therapeutics Holdings Inc. Announces the Addition of Two New Clinical Consultants to Continue the Advancement of Our Lead Anti-G-CSF Antibody Candidate Towards a First-in-Human Clinical Trial @MeTherapeutics #Chemicals #Biotechnology #CSEStocks #SmallCaps #Investing

Vancouver, British Columbia--(Newsfile Corp. - May 29, 2024) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announce that the Company has engaged two new clinical consultants to help advance our lead anti-G-CSF antibody candidate (h1B11-12) towards a first in-human clinical trial.Dr. Kate Hanham, PhD, is a clinical trial...


http://dlvr.it/T7YSkz

Comments

Popular posts from this blog

SEC Investor Advisory Committee to Discuss Exempt Offerings and Accredited Investors at September 21 Meeting #Banking #FinancialServices

Cleantek Industries Inc. Announces a Twelve-Month Extension of Credit Facility #CTEK.CA #CTEK.V #GLKFF #Investing #OTC #OTCMarkets #OTCStocks #SmallCaps #TSXV #Technology

Hearts Connect along the Silk Road, International Voluntary Service Seminar Held in Nanjing #